You are here: Industry Insights > Pharma in China > Chinese-produced new drugs to be marketed soon in 2019

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Chinese-produced new drugs to be marketed soon in 2019

PharmaSources/CaicaiJanuary 21, 2019

Tag: new drugs , 2019 , Chinese-produced Drug

Favorites

Chinese-produced new drugs to be marketed soon in 2019:

Chinese-produced new drugs to be marketed soon in 2019

Pharmaceutical product name	Mechanism of action	Registration classification	Company
Polyethylene Glycol Loxenatide Injection	Long-acting GLP-1 receptor agonist	Chemical drug 1	Hansoh
Utidelone Injection	Non-taxane tubulin polymerization-resistant antitumor drug	Chemical drug 1	Biostar
Camrelizumab for Injection	Anti-PD-1 antibody	Biological product for treatment1	Jiangsu Suncadia
Avitinib Maleate Capsules	Third-generation EGFR TKI	Chemical drug 1	ACEA Pharma
Fumaritidine Mesylate Tablets	Second-generation Bcr-Abl TKI	Chemical drug 1	Hansoh
Zanubrutinib Capsules	BTK inhibitor	Chemical drug 1	BeiGene
Tislelizumab Injection	Anti-PD-1 antibody	Biological product for treatment 1	BeiGene, Celgene, Boehringer Ingelheim
Sodium Oligomannurarate Capsules	Marine oligosaccharide molecule	Chemical drug 1	Chinese Academy of Sciences and GreenValley

(Sorted out based on public data. Any supplementation will be much appreciated. *Jiangsu Suncadia is a subsidiary of Hengrui Medicine)

About the Author:

Caicai, a Master of Pharmacy from Shanghai Jiaotong University, used to work in the Institute of Science and Technical Information. Currently as a practitioner in the drug surveillance system, she is good at interpreting industry regulations, pharmaceutical research developments, etc.

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.

Previous:Preparing samples of cannabis plant for THC/CBD analysis

Next:Chinese-produced New Drugs Approved for Marketing in 2018

Has the booming PD-1 inhibitor reached its limit?

Krebs QinOctober 18, 2024

In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.

Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology

Krebs QinOctober 18, 2024

What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca?

wanOctober 18, 2024

Chinese-produced new drugs to be marketed soon in 2019 | Pharmasources.com

Where Lies the Competitiveness of China's New Drugs for Central Nervous System?

Prof. ZhangOctober 18, 2024

The Global Challenges and Opportunities of the R&D of New Drugs for Central Nervous System

Chinese-produced new drugs to be marketed soon in 2019

About the Author:

Related News

Has the booming PD-1 inhibitor reached its limit?

Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology

What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca?

Where Lies the Competitiveness of China's New Drugs for Central Nervous System?

You may like
More>>

Chinese-produced new drugs to be marketed soon in 2019

About the Author:

Related News

Has the booming PD-1 inhibitor reached its limit?

Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology

What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca?

Where Lies the Competitiveness of China's New Drugs for Central Nervous System?

You may likeMore>>

You may like
More>>